Health Care & Life Sciences » Biotechnology | Biocon Ltd.

Biocon Ltd. | Income Statement

Fiscal year is April-March. All values INR Millions.
2014
2015
2016
2017
2018
Sales/Revenue
28,513
30,592
33,474
38,911
40,316
Cost of Goods Sold (COGS) incl. D&A
21,467
22,984
25,109
28,439
32,491
Gross Income
7,046
7,608
8,365
10,472
7,825
SG&A Expense
3,773
4,085
4,287
4,578
5,909
EBIT
3,127
3,321
-
5,894
1,916
Unusual Expense
-
218
1,606
132
58
Non Operating Income/Expense
2,154
3,107
1,477
1,453
4,143
Interest Expense
17
89
293
260
657
Pretax Income
5,377
6,241
7,296
8,334
5,887
Income Tax
1,069
957
1,422
1,616
1,569
Equity in Affiliates
-
-
217
163
213
Consolidated Net Income
4,308
5,284
6,091
6,881
4,531
Net Income
4,138
4,974
5,504
6,121
3,724
Net Income After Extraordinaries
4,138
4,974
5,504
6,121
3,724
Net Income Available to Common
4,138
4,974
5,504
6,121
3,724
EPS (Basic)
7.03
8.29
9.35
10.39
6.31
Basic Shares Outstanding
589
600
589
589
590
EPS (Diluted)
6.95
8.29
9.34
10.32
6.27
Diluted Shares Outstanding
595
600
589
593
594
EBITDA
5,163
5,531
6,565
8,666
5,767
Other Operating Expense
146
202
-
-
-
Non-Operating Interest Income
113
120
428
1,115
427
Minority Interest Expense
170
310
587
760
807

About Biocon

View Profile
Address
20th KM, Hosur Road
Bangalore Karnataka 560100
India
Employees -
Website http://www.biocon.com
Updated 09/14/2018
Biocon Ltd. is a holding company, which engages in the manufacture, research, and development of therapeutic drugs. It operates through the following segments: Small Molecules, Biologics, Branded Formulations, and Research Services. The Small Molecules segment manufactures spanning statins, immunosuppressants, antifungals, anti-obesity, anti-diabetics, ophthalmologicals, oncologicals, and urologicals etc.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.